<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are clonal disorders that result in cytopenias and risk of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Incidence increases with age and more diagnoses are expected with the aging population </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment includes red blood cell transfusion for <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The immunomodulatory agents (imids) thalidomide and lenalidomide may induce transfusion independence </plain></SENT>
<SENT sid="4" pm="."><plain>This guideline systematically reviews evidence on imids to treat <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and makes evidence-based recommendations </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: The literature and meeting abstracts were searched for phase 2-3 clinical trials </plain></SENT>
<SENT sid="6" pm="."><plain>Data on efficacy, toxicity, and which patients benefit were extracted </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: 7019 citations on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> management were identified </plain></SENT>
<SENT sid="8" pm="."><plain>Thirteen publications and 9 meeting abstracts met eligibility criteria </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Lenalidomide is recommended as first line therapy in lower risk del5q <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>There is insufficient evidence to recommend lenalidomide for treatment of higher risk del5q <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, or for any risk non-del5q <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Combining lenalidomide with other agents is not recommended </plain></SENT>
<SENT sid="12" pm="."><plain>Thalidomide is not recommended </plain></SENT>
</text></document>